Citation: E. Mohr, WHAT IS THE MEANING OF ]]NORMAL[[ - A COM MENTARY ON THE NORMAL RANGES OF CLINICAL-PATHOLOGICAL DIAGNOSTIC PARAMETERS FOR SHEEP, Tierarztliche Umschau, 51(4), 1996, pp. 229-232
Citation: Jj. Claus et E. Mohr, ATTENTIONAL DEFICITS IN ALZHEIMERS, PARKINSONS, AND HUNTINGTONS DISEASES, Acta neurologica Scandinavica, 93(5), 1996, pp. 346-351
Authors:
LATOUR P
BELAICHE J
LOUIS E
FONTAINE F
DEFLANDRE J
LOLY J
OGER A
DEFRANCE P
DIVALENTIN A
DELFORGE M
DAENEN G
LEBAS M
MOHR E
WAIN E
GILLARD C
THYS C
Citation: P. Latour et al., INCIDENCE OF INFLAMMATORY BOWEL-DISEASE IN THE PROVINCE OF LIEGE (BELGIUM), Acta Gastro-Enterologica Belgica, 59(1), 1996, pp. 3-6
Citation: E. Mohr, GREENHOUSE POLICY PERSUASION - TOWARDS A POSITIVE THEORY OF DISCOUNTING THE CLIMATE FUTURE, Ecological economics, 15(3), 1995, pp. 235-245
Authors:
BRAUN AR
RANDOLPH C
STOETTER B
MOHR E
COX C
VLADAR K
SEXTON R
CARSON RE
HERSOVITCH P
CHASE TN
Citation: Ar. Braun et al., THE FUNCTIONAL NEUROANATOMY OF TOURETTES-SYNDROME - AN FDG-PET STUDY .2. RELATIONSHIPS BETWEEN REGIONAL CEREBRAL METABOLISM AND ASSOCIATED BEHAVIORAL AND COGNITIVE FEATURES OF THE ILLNESS, Neuropsychopharmacology, 13(2), 1995, pp. 151-168
Authors:
MOHR E
KNOTT V
SAMPSON M
WESNES K
HERTING R
MENDIS T
Citation: E. Mohr et al., COGNITIVE AND QUANTIFIED ELECTROENCEPHALOGRAPHIC CORRELATES OF CYCLOSERINE TREATMENT IN ALZHEIMERS-DISEASE, Clinical neuropharmacology, 18(1), 1995, pp. 28-38
Citation: E. Mohr et al., CANADIAN GUIDELINES FOR THE DEVELOPMENT OF ANTIDEMENTIA THERAPIES - ACONCEPTUAL SUMMARY, Canadian journal of neurological sciences, 22(1), 1995, pp. 62-71
Citation: E. Mohr et al., DIFFERENTIAL SUBCELLULAR MESSENGER-RNA TARGETING - DELETION OF A SINGLE NUCLEOTIDE PREVENTS THE TRANSPORT TO AXONS BUT NOT TO DENDRITES OF RAT HYPOTHALAMIC MAGNOCELLULAR NEURONS, Proceedings of the National Academy of Sciences of the United Statesof America, 92(10), 1995, pp. 4377-4381
Citation: Pc. Svane et al., EFFECT OF HYPOOSMOLALITY ON THE ABUNDANCE, POLY(A) TAIL LENGTH AND AXONAL TARGETING OF ARGININE-VASOPRESSIN AND OXYTOCIN MESSENGER-RNAS IN RAT HYPOTHALAMIC MAGNOCELLULAR NEURONS, FEBS letters, 373(1), 1995, pp. 35-38
Citation: Se. Purdon et al., HUNTINGTONS-DISEASE - PATHOGENESIS, DIAGNOSIS AND TREATMENT, Journal of psychiatry & neuroscience, 19(5), 1994, pp. 359-367
Authors:
PURDON SE
JONES BD
BEGIN L
LABELLE A
MOHR E
Citation: Se. Purdon et al., FRONTAL MEDIATION OF NEW LEARNING IN HUNTINGTONS-DISEASE AND SCHIZOPHRENIA, Schizophrenia research, 11(2), 1994, pp. 152-152
Authors:
MENDIS T
MOHR E
GEORGE A
RUSK IN
GRAY P
GRIMES JD
Citation: T. Mendis et al., SYMPTOMATIC RELIEF FROM TREATMENT-INDUCED PSYCHOSIS IN PARKINSONS-DISEASE - AN OPEN-LABEL PILOT-STUDY WITH REMOXIPRIDE, Movement disorders, 9(2), 1994, pp. 197-200
Citation: E. Mohr et al., SOMATIC NONHOMOLOGOUS CROSSING-OVER BETWEEN NEUROPEPTIDE GENES IN RATHYPOTHALAMIC NEURONS, Proceedings of the National Academy of Sciences of the United Statesof America, 91(24), 1994, pp. 11403-11407
Citation: L. Mcfadden et al., SCREENING FOR COGNITIVE DYSFUNCTION IN NEURODEGENERATIVE ILLNESS, Journal of Neurology, Neurosurgery and Psychiatry, 57(10), 1994, pp. 1282-1282
Citation: C. Randolph et al., ASSESSMENT OF INTELLECTUAL FUNCTION IN DEMENTING DISORDERS - VALIDITYOF WAIS-R SHORT FORMS FOR PATIENTS WITH ALZHEIMERS HUNTINGTONS, AND PARKINSONS-DISEASE, Journal of clinical and experimental neuropsychology, 15(5), 1993, pp. 743-753